Publication | Closed Access

Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer

Trastuzumab ResistanceCancer Stem-like PropertiesOncologyBreast OncologyDrug TargetingMedicineBreast CancerAnti-cancer AgentCancer TreatmentRadiation OncologyCancer BiologyCell BiologyTumor BiologyHer2-positive Breast Cancer